26,183 Shares in Anika Therapeutics Inc. $ANIK Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 26,183 shares of the biotechnology company’s stock, valued at approximately $383,000.

A number of other hedge funds also recently bought and sold shares of ANIK. Quarry LP acquired a new stake in shares of Anika Therapeutics in the third quarter valued at about $71,000. CWM LLC lifted its position in shares of Anika Therapeutics by 14.5% during the 4th quarter. CWM LLC now owns 8,537 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 1,080 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Anika Therapeutics during the 3rd quarter worth about $95,000. Ieq Capital LLC bought a new stake in Anika Therapeutics during the 4th quarter valued at approximately $97,000. Finally, Inscription Capital LLC bought a new stake in Anika Therapeutics during the 4th quarter valued at approximately $122,000. 91.53% of the stock is currently owned by institutional investors.

Anika Therapeutics Stock Up 2.1%

Shares of ANIK opened at $21.78 on Friday. Anika Therapeutics Inc. has a 12-month low of $8.37 and a 12-month high of $22.88. The firm has a market capitalization of $291.42 million, a price-to-earnings ratio of -80.66, a P/E/G ratio of 15.56 and a beta of 0.20. The stock’s 50-day moving average price is $17.05 and its 200 day moving average price is $14.98.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.03 by $0.39. Anika Therapeutics had a positive return on equity of 0.20% and a negative net margin of 3.14%.The firm had revenue of $32.61 million during the quarter, compared to analysts’ expectations of $29.21 million. Equities research analysts expect that Anika Therapeutics Inc. will post 0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ANIK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Wednesday, June 24th. B. Riley Financial increased their price objective on Anika Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Barrington Research set a $21.00 target price on shares of Anika Therapeutics in a research report on Thursday, July 30th. Zacks Research upgraded shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Anika Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.